Arch Biopartners Inc. develops therapeutics for acute kidney injury and chronic kidney disease. Company news centers on LSALT peptide for cardiac surgery-associated acute kidney injury, cilastatin for drug-toxin-related acute kidney injury, and a chronic kidney disease platform tied to interleukin-32.
Recurring updates include clinical trial agreements, ethics and operational approvals, hospital site activity, patient recruitment and dosing milestones, drug-product manufacturing for cilastatin, patent filings connected with the CKD platform, and board governance changes. The company’s disclosures also describe acute kidney injury mechanisms such as ischemia-reperfusion injury, nephrotoxic pharmaceuticals, and inflammation-related kidney damage.
Arch Biopartners Inc. has commenced its Phase II trial of LSALT peptide, aimed at preventing acute lung and kidney injuries in COVID-19 patients. The first patient was dosed at Broward Health Medical Center, with recruitment expanding soon to Louisiana and Turkey. This international, double-blind trial will assess LSALT's efficacy in mitigating severe organ inflammation connected to COVID-19 complications. Results will inform the design of a subsequent Phase III trial, which will involve a larger patient population.
Arch Biopartners Inc. (OTCQB: ACHFF) has received approval from Turkey's Ministry of Health to proceed with a Phase II trial for its LSALT peptide drug, targeting acute lung and kidney injuries related to COVID-19. Patient enrollment will commence in Istanbul and Ankara, amidst rising COVID-19 cases in Turkey. In the U.S., patient screening has begun at a hospital site in Florida, with plans to activate two more sites. The trial aims to assess the LSALT peptide's efficacy in preventing organ inflammation in COVID-19 patients, impacting future Phase III study designs.